(NASDAQ: STRO) Sutro Biopharma's forecast annual revenue growth rate of -29.78% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.06%.
Sutro Biopharma's revenue in 2024 is $153,731,000.On average, 7 Wall Street analysts forecast STRO's revenue for 2024 to be $5,021,145,571, with the lowest STRO revenue forecast at $1,498,607,112, and the highest STRO revenue forecast at $13,416,280,170. On average, 6 Wall Street analysts forecast STRO's revenue for 2025 to be $4,179,178,142, with the lowest STRO revenue forecast at $940,750,615, and the highest STRO revenue forecast at $12,791,860,540.
In 2026, STRO is forecast to generate $3,321,038,244 in revenue, with the lowest revenue forecast at $483,300,794 and the highest revenue forecast at $8,108,713,315.